Table 6.
Study | Sample | Database | Neuropathological criteria | Autopsy | Dementia criteria |
---|---|---|---|---|---|
McKeith
et al
., 1992 [[20]] |
AD 37 |
Newcastle, UK |
AD: plaque/tangle quantification, H + E, CFV, Loyez, Palmgren. |
All |
DLB: proposed consensus (1992) |
SDLT 21 | |||||
LB: H + E, pholxine, erythrosin | |||||
Ballard
et al
., 1996 [[17]] |
AD 53 |
West Midlands and Bristol, UK |
|
0 |
AD: NINCDS/ADRDA (1984) |
SDLT 7 |
DLB: McKeith, operational criteria for senile dementia of Lewy body type (1992) |
||||
VaD 14 | |||||
Ballard et al., 1998 [[21]] |
AD 30 |
Newcastle General Hospital, UK |
AD: CERAD, plaque – Braunmuhl stain, tangle – modified Palmgren |
19 |
AD: NINCDS/ADRDA (1984) |
DLB 42 |
DLB: McKeith, operational criteria for senile dementia of Lewy body type (1992) |
||||
LB: consensus criteria (1996), ubiquitin, anti-tau2, anti-Alz50, anti-AT8 to detect and distinguish cortical LB | |||||
Olichney
et a
l., 1998 [[3]] |
AD 148 |
Cohort from: |
AD: CERAD, ADRC |
All |
AD: NINCDS/ADRDA (1984), |
LBV 40 |
Univeristy of California, San Diego Alzheimer’s Disease Research Center, USA; |
LB: ubiquitin, H + E (brainstem, cerebral cortex) |
DSM-III for dementia |
||
CERAD centers, multinational | |||||
Heyman
et al
., 1999 [[18]] |
AD 74 |
Subjects with premortem diagnosis of probable and possible AD from 24 centers participating in CERAD, 1986 to 1995, USA |
AD: CERAD |
All |
AD: NINCDS/ADRDA (1984) |
AD/LBV 27 |
LB: consensus criteria (1996), modified (brainstem, limbic/transitional and noecortical). |
||||
Lopez
et al
., 2000 [[22]] |
AD 98 |
University of Pittsburg 1983 to 1998, USA |
AD: CERAD, NIA-RI |
All |
AD: NINCDS/ADRDA (1984) |
AD/DLB 44 |
LB: H + E, ubiqutin (SN, neocortex, limbic areas) |
DLB: consensus criteria (1996) |
|||
Stern
et al
. 2001 [[23]] |
AD 32 |
From cohort of 236 patients with probable AD |
AD: CERAD |
All |
AD: NINCDS/ADRDA (1984) |
LBV 19 |
LB: semi quantitative ubiquitin (SN, hippocampus, cingulate gyrus, insula cortex) |
||||
Recruited: | |||||
Columbia University College, New York, USA | |||||
Johns Hopkins University, Baltimore, USA | |||||
Massachusetts General Hospital, Boston, USA | |||||
Ballard
et al
., 2001 [[24]] |
AD 101 |
Cohort of 227 patients |
AD: CERAD, plaque - Braunmuhl stain, tangle - modified Palmgren |
50 |
AD: NINCDS/ADRDA (1984) |
DLB 64 |
Institute of the Health of the Elderly (IHE), Newcastle, UK |
DLB: consensus criteria (1996) |
|||
VaD 38 |
LB: consensus criteria (1996), ubiquitin, anti-tau2, anti-Alz50, anti-AT8 to detect and distinguish cortical LB |
||||
Helmes
et al
., 2003 [[25]] |
AD 15 |
University of Western Ontario Dementia Study, Canada |
No criteria are referred to. Only referred to LB staining methods (Bielschovsky, anti-ubiquitin, anti-synuclein). |
All |
Not specified. |
AD/DLB 8 | |||||
DLB 7 | |||||
Johnson
et al
., 2005 [[26]] |
AD 66 |
Washington University, from 1979, USA |
AD: NIA-RI quantification of diffuse and neuritic depositions in 10 cortical regions |
All |
AD: NINCDS/ADRDA (1984) |
AD/DLB 57 |
DLB: consensus criteria (1996) or McKeith, operational criteria for senile dementia of Lewy body type (1992) |
||||
DLB 9 |
LB: synuclein |
||||
Kraybill
et al
., 2005 [[15]] |
AD 48 |
Cohort from University of Washington/Group Health Cooperative Alzheimer’s Disease Patient Registry, USA |
AD: CERAD, Braak stages > IV |
All |
AD: NINCDS/ADRDA (1984) |
AD/LBP 65 |
LB/AD: AD + synuclein (amygdala, SN) |
DLB: missing criteria because study was started before the consensus criteria for DLB was established. |
|||
LBP 22 | |||||
LB: Braak stages < III, synuclein (amygdala, SN) | |||||
Stavitsky
et a
l., 2006 [[19]] |
AD 55 |
Cohort of the Predictors Study, 1997: |
AD: CERAD |
12 |
AD: NINCDS/ADRDA (1984) |
DLB 28 |
LB: semi quantitative ubiquitin (hippocampus, cingulate gyrus, insula cortex) |
DLB: consensus criteria (1996) |
|||
Columbia University | |||||
Johns Hopkins University, | |||||
Massachusetts General Hospital, USA | |||||
Williams
et al
., 2006 [[27]] |
AD 252 |
Cohort from Washington University, USA |
AD: NIA-RI quantification of diffuse and neuritic depositions in 10 cortical regions |
All |
AD: NINCDS/ADRDA (1984) |
DLB 63 |
DLB: consensus criteria (1996) |
||||
LB: synuclein | |||||
Hamilton
et al
., 2008 [[28]] |
AD 44 |
University of California, Alzheimer’s disease center San Diego, 1985 to 2002, USA |
AD: modified Braak staging, NIA-RI (1997) and CERAD (1991) |
All |
AD: NIA-RI and CERAD (1988) |
DLB 22 |
DLB: consensus criteria (1996) |
||||
LB: H + E, ubiquitin (1996) synuclein (2005) | |||||
Hanyu
et al
., 2009 [[29]] |
AD 111 |
Memory Clinic of Tokyo Medical University, 2000 to 2006, Japan |
|
0 |
AD: NINCDS/ADRDA (1984) |
DLB 56 |
DLB: consensus criteria (1996) |
||||
Nelson
et al
., 2009 [[16]] |
AD 107 |
National Alzheimer’s Coordinating Center (NACC) Registry - 31 AD centers in USA, |
AD: NIA-RI |
All |
AD: CERAD (1988) |
AD/DLB 27 |
University of Kentucky Alzheimer’s Disease Center, USA |
LB: Braak staging and CERAD |
DLB: consensus criteria (1996) |
||
DLB 9 | |||||
Wood
et a
l., 2012 [[30]] |
AD 16 |
Newcastle University, UK |
|
0 |
AD: NINCDS/ADRDA (1984) |
DLB 12 |
DLB: consensus criteria (2005) or (1996) |
||||
Walker et al . 2012 [[31]] | AD 100 |
40 European sites | 123I-FTP-SPECT as verifying method | 0 | AD: NINCDS/ADRDA (1984) |
DLB 58 | DLB: consensus criteria (1996) |
AD, Alzheimer’s disease; ADRC, Alzheimer’s Disease Research Center; CERAD, The Consortium to Establish a Registry for Alzheimer's Disease; CFV, creasyl fast violet; DLB, dementia with Lewy bodies; H + E, hematoxylin and eosin staining; I-FTP-SPECT, ioflupane single-photon emission computed tomography; LB Lewy body; LBV, Lewy body variant; LBP, Lewy body pathology; NIA-RI, National Institute on Aging-Reagan; NINCDS/ADRDA, National Institute of Neurological and Communication Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association; SDLT, senile dementia of Lewy body type; SN, substantia nigra.